Dr Carey on Response-Guided Therapy in HER2+ Breast Cancer
Lisa A. Carey MD, ScM, FASCO, discusses the varying approaches to response-guided therapy in HER2-positive breast cancer.
Stay updated with breaking news from Clinical Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lisa A. Carey MD, ScM, FASCO, discusses the varying approaches to response-guided therapy in HER2-positive breast cancer.
A one-time treatment with isolated hepatic perfusion with melphalan improved median progression-free survival compared with best alternative treatment for patients with previously untreated isolated liver metastases from uveal melanoma.
Families which let their children have more screen time might be experiencing food or housing challenges.
Other sex hormones had no effect, according to researchers.
/PRNewswire/ -- The ERP Biomarker Qualification Consortium announced today the publication of all data (https://doi.org/10.1016/j.schres.2023.02.018) from a...